Overview

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

Status:
Completed
Trial end date:
2012-10-17
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of California, Davis
Treatments:
Omalizumab
Criteria
Inclusion Criteria:

- Mild or moderate persistent asthma

- Allergic rhinitis

- Atopic dermatitis

Exclusion Criteria:

- Other lung diseases

- Blood clotting disorder

- Pregnant or lactating women